Consolidated Balance Sheets - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 56.9	$ 257.4
Marketable investment securities	58.0	81.4
Trade accounts receivable	101.6	91.3
Inventory	20.1	15.3
Prepaid taxes	17.6	18.4
Prepaid expenses and other current assets	20.4	21.0
Total current assets	274.6	484.8
Operating lease right-of-use assets	103.9	81.8
Long-term marketable investment securities	54.8	59.0
Property, plant and equipment, net	83.4	43.5
Intangibles, net	379.7	404.1
Goodwill	286.8	239.2
Other assets	15.5	8.3
Total assets	1,198.7	1,320.7
Current liabilities:
Accounts payable	28.8	29.6
Accrued liabilities	94.3	161.7
Current maturities of operating lease liabilities	14.1	13.0
Total current liabilities	137.2	204.3
Unrecognized tax benefits	26.8	27.9
Long-term deferred taxes	3.5	35.8
Noncurrent operating lease liabilities	130.9	79.3
Other long-term liabilities	14.5	5.6
Total liabilities	312.9	352.9
Commitments and contingencies
Stockholders’ equity:
Common stock, $0.01 par value, 81.2 and 80.0 shares outstanding at December 31, 2022 and 2021, respectively	0.8	0.8
Additional paid-in capital	1,260.1	1,226.3
Accumulated other comprehensive loss	(8.9)	(5.1)
Accumulated deficit	(366.2)	(254.2)
Total Myriad Genetics, Inc. stockholders' equity	885.8	967.8
Non-controlling interest	0.0	0.0
Total stockholders' equity	885.8	967.8
Total liabilities and stockholders’ equity	$ 1,198.7	$ 1,320.7

Unrecognized Tax Benefits, Net

No definition available.

Name:	mygn_UnrecognizedTaxBenefitsNet
Namespace Prefix:	mygn_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).